OBJECTIVES: To evaluate the cost-effectiveness of ceftazidime/avibactam versus meropenem in the treatment of complex intra-abdominal infections (cIAIs) in China.

METHODS: Based on a systematic review comparing the effectiveness and safety of ceftazidime/avibactam and carbapenems in the treatment of cIAIs (including 4 randomized controlled trials), a 21d study period was used to establish a decision tree model using Treeage 2011 software , Judge the economics of the plan with the incremental cost-effectiveness ratio, and conduct single-factor sensitivity analysis and probability sensitivity analysis.

RESULTS: The cost-effectiveness analysis showed that the CER of ceftazidime/avibactam for cIAIs was 101526.19 yuan, and the cure rate was 92.27%; the CER of meropenem for cIAIs was 70153.33 yuan, and the cure rate was 91.86%. Using 3 times China's per capita GDP in 2020 (212,676 yuan) as WTP, the ICER of ceftazidime/avibactam versus meropenem is 7130578.049 yuan, which is higher than China's WTP, and the additional cost is not worthwhile. The results of single-factor sensitivity analysis showed that the average daily cost of ceftazidime/avibactam had the greatest impact on the results; the results of the probabilistic sensitivity analysis were stable. When the WTP fluctuates in the range of 0-212676 yuan/case, the treatment of cIAIs by meropenem has The probability of cost-effectiveness is always greater than ceftazidime/avibactam treatment and is 100%.

CONCLUSIONS: Ceftazidime/avibactam versus meropenem is not economical in the treatment of cIAIs.